Abstract
Circulating anti-p53 antibodies have been described and used as tumoural markers in patients with various cancers and strongly correlate with the p53 mutated status of the tumours. No study has yet looked at the prevalence of such antibodies in skin carcinoma patients although these tumours have been shown to be frequently p53 mutated. Most skin carcinoma can be diagnosed by examination or biopsy, but aggressive, recurrent and/or non-surgical cases’ follow up would be helped by a biological marker of residual disease. We performed a prospective study looking at the prevalence of anti-p53 antibodies using an ELISA technique in a series of 105 skin carcinoma patients in comparison with a sex- and age-matched control skin carcinoma-free group (n = 130). Additionally, p53 accumulation was studied by immunohistochemistry to confirm p53 protein altered expression in a sample of tumours. Anti-p53 antibodies were detected in 2.9% of the cases, with a higher prevalence in patients suffering from the more aggressive squamous cell type (SCC) of skin carcinoma (8%) than for the more common and slowly growing basal cell carcinoma type or BCC (1.5%). p53 protein stabilization could be confirmed in 80% of tumours studied by IHC. This low level of anti-p53 antibody detection contrasts with the high rate of p53 mutations reported in these tumours. This observation shows that the anti-p53 humoral response is a complex and tissue-specific mechanism. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Angelopoulou K, Diamandis EP, Sutherland DJA, Kellen JA and Bunting PS (1994) Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 58: 480–487
Basset-Séguin N, Molés JP, Mils V, Dereure O and Guilhou JJ (1994) TP53 tumor suppressor gene and skin carcinogenesis. J Invest Dermatol 103: 102S–106S
Beissert S and Schwarz T (1999) Mechanism involved in ultraviolet light-induced immunosuppression. J Invest Dermatol Symp Proceed 4: 61–64
Bourhis J, Lubin R, Roche B, Koscienly S, Bosq J, Dubois I, Talbot M, Marandas P, Schwaab G, Wibault P, Luboinski B, Eschwege F and Soussi T (1996) Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J Nat Cancer Inst 88: 1228–1233
Collet B, Raoul JL, Le Berre N, Heresbach D, Meritte H, Quillien V and de Certaines JD (1997) Serum anti-p53 antibodies in patients with squamous cell carcinoma of the esophagous: Comparison with p53 alterations and lymph node invasion. Int J Oncol 11: 617–621
Crawford LV, Pim DC and Bulbrook RD (1982) Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30: 403–408
Firestein GS, Nguyen K, Aupperle KR, Yeo M, Boyle DL and Zvaifler N (1996) Apoptosis in rhumatoid arthritis. p53 overexpression in rheumatoid arthritis synovium. Am J Pathol 149: 2143–2151
Hammel P, Boissier B, Chaumette MT, Piedbois P, Rotman N, Kouyoumdjian JC, Lubin R, Delchier JC and Soussi T (1997) Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut 40: 356–361
Hammel P, Leroy-Viard K, Chaumette MT, Villaudy J, Falzone MC, Rouillard D, Hamelin R, Boissier B and Remvikos Y (1999) Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer. Int J Cancer 81: 712–718
Hollstein M, Sidransky D, Vogelstein B and Harris C (1991) p53 mutations in human cancers. Science 253: 49–53
Kaur J, Srivastava A and Ralhan R (1997) Serum p53 antibodies in patients with oral lesions: correlation with p53/HSP70 complexes. Int J Cancer (Pred Oncol) 74: 609–613
Lubin R, Zalcman G, Bouchet L, Trédaniel J, Legros Y, Cazals D, Hirsch A and Soussi T (1995) Serum p53 antibodies as early markers of lung cancer. Nat Med 1: 701–702
Peyrat JP, Bonneterre J, Lubin R, Vanlemmens L, Fournier J Soussi (1995) Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 345: 621–622
Rainov NG, Dobberstein KU, Fittkau M, Bahn H, Holzausen HJ, Gantchev L and Burkert W (1995) Absence of p53 antibodies in sera from glioma patients. Clin Cancer Res 1: 775–781
Ren ZP, Hedrum A, Ponten F, Nister M, Ahmadian A, Lundeberg J, Uhlen M and Ponten J (1996) Human epidermal cancer and accompanying precursors have identical p53 mutations different from p53 mutations in adjacent areas of clonally expanded non-neoplasic keratinocytes. Oncogene 12: 765–773
Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F and Soussi T (1992) The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52: 6380–6384
Soussi T (2000) p53 antibodies in the sera of patients with various types of cancer: A Review. Cancer Research 60: 1777–1788
Zalcman G, Schlichtholz B, Trédaniel J, Urban T, Lubin R, Dubois I, Milleron B, Hirsch A and Soussi T (1998) Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment. Clin Can Res 4: 1359–1366
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Moch, C., Moysan, A., Lubin, R. et al. Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies. Br J Cancer 85, 1883–1886 (2001). https://doi.org/10.1054/bjoc.2001.2185
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2185